UM

Browse/Search Results:  1-5 of 5 Help

Selected(0)Clear Items/Page:    Sort:
TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance Journal article
Jiang, XM, Xu, YL, Yuan, LW, Zhang, LL, Huang, MY, Ye, ZH, Su, MX, Chen, X. P., Zhu, H, Ye, R, Lu, J.. TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance[J]. Acta Pharmacologica Sinica, 2020, 451-459.
Authors:  Jiang, XM;  Xu, YL;  Yuan, LW;  Zhang, LL;  Huang, MY; et al.
Favorite |  | Submit date:2022/08/26
Egfr Mutant Non-small Cell Lung Cancer  Nf-κb  Tgfβ2  Epithelial-mesenchymal Transition  Osimertinib Resistance  
23-乙醯澤瀉醇B調節腫瘤細胞自噬 Conference paper
Xu, YL, Jiang, XM, Zhang, LL, Chen, X. P., Wang, Y. T., Lu, J.. 23-乙醯澤瀉醇B調節腫瘤細胞自噬[C], 2017.
Authors:  Xu, YL;  Jiang, XM;  Zhang, LL;  Chen, X. P.;  Wang, Y. T.; et al.
Favorite |  | Submit date:2022/08/26
腫瘤  23-乙醯澤瀉醇B  自噬  JNK  c-Jun  
奧斯替尼誘導腫瘤細胞自噬及其耐藥細胞的特徵 Conference paper
Tang, ZH, Jiang, XM, Cao, WX, Lu, J.. 奧斯替尼誘導腫瘤細胞自噬及其耐藥細胞的特徵[C], 2017.
Authors:  Tang, ZH;  Jiang, XM;  Cao, WX;  Lu, J.
Favorite |  | Submit date:2022/08/26
奧斯替尼  自噬  活性氧  耐藥  EGFR  
Treatment of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells by targeting inositol-requiring enzyme 1α Conference paper
Tang, ZH, Su, MX, Guo, XH, Jiang, XM, Chen, X. P., Lu, J.. Treatment of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells by targeting inositol-requiring enzyme 1α[C], 2016.
Authors:  Tang, ZH;  Su, MX;  Guo, XH;  Jiang, XM;  Chen, X. P.; et al.
Favorite |  | Submit date:2022/08/26
osimertinib  AZD9291  EGFR  IRE1α  NSCLC  
Characterization of osimertinib (AZD9291)-resistant non-small-cell lung cancer NCI-H1975/OSIR cell line Conference paper
Tang, ZH, Jiang, XM, Guo, X, Fong, CM, Wang, ZY, Chen, X. P., Lu, J.. Characterization of osimertinib (AZD9291)-resistant non-small-cell lung cancer NCI-H1975/OSIR cell line[C], 2016.
Authors:  Tang, ZH;  Jiang, XM;  Guo, X;  Fong, CM;  Wang, ZY; et al.
Favorite |  | Submit date:2022/08/26
osimertinib  resistance  EGFR  ABT-263